Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders??? Equity

v3.24.2.u1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
Total
Preferred Stock
Series A Preferred Stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series C Preferred Stock
Preferred Stock
Series D Preferred Stock
Preferred Stock
Series E Preferred Stock
Preferred Stock
Series F Preferred Stock
Preferred Stock
Series F-1 Preferred Stock
Preferred Stock
Series F-2 Preferred Stock
Common Stock
Common Stock
Series A Preferred Stock
Common Stock
Series B Preferred Stock
Common Stock
Series C Preferred Stock
Common Stock
Series F Preferred Stock
Common Stock
Series F-1 Preferred Stock
Common Stock
Series F-2 Preferred Stock
Common Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022   251 1,443 500,756 1,058 0 0 0 0 2,257                  
Balance as of beginning of period at Dec. 31, 2022 $ 530,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 2,000               $ 88,533,000 $ (88,005,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Exercise of common stock warrants (in shares)                   729                  
Exercise of common stock warrants 2,062,000                 $ 1,000               2,061,000  
Issuance of common stock in connection with conversion of notes (in shares)                   210                  
Issuance of common stock in connection with conversion of notes 516,000                                 516,000  
Net proceeds on sales (in Shares)                   1,412                  
Issuance of common stock/at-the-market offering, net of offering costs 2,107,000                 $ 1,000               2,106,000  
Issuance of Series E preferred stock in connection with LOC (in shares)           5,000                          
Issuance of Series E preferred stock in connection with LOC 4,350,000                                 4,350,000  
Deemed dividend for repricing of Series D preferred stock 0                                 6,000 (6,000)
Commitment to issue shares of common stock in connection with March waiver agreement 298,000                                 298,000  
Stock-based compensation (in shares)                   265                  
Stock-based compensation 181,000                                 181,000  
Net loss (2,300,000)                                   (2,300,000)
Ending balance (in shares) at Mar. 31, 2023   251 1,443 500,756 1,058 5,000 0 0 0 4,873                  
Balance as of ending of period at Mar. 31, 2023 7,744,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 4,000               98,051,000 (90,311,000)
Beginning balance (in shares) at Dec. 31, 2022   251 1,443 500,756 1,058 0 0 0 0 2,257                  
Balance as of beginning of period at Dec. 31, 2022 530,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 2,000               88,533,000 (88,005,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net loss (16,819,000)                                    
Ending balance (in shares) at Jun. 30, 2023   251 1,443 500,756 0 0 5,251 3,583 1,153 7,139                  
Balance as of ending of period at Jun. 30, 2023 4,557,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 6,000               109,381,000 (104,830,000)
Beginning balance (in shares) at Mar. 31, 2023   251 1,443 500,756 1,058 5,000 0 0 0 4,873                  
Balance as of beginning of period at Mar. 31, 2023 7,744,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 4,000               98,051,000 (90,311,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Issuance of common stock in connection with conversion of october Notes (in shares)                   50                  
Issuance of common stock upon the conversion of Series E preferred stock 1,000                 $ 1,000                  
Issuance of common stock in connection with conversion of October Notes (in shares)                   1,660                  
Issuance of common stock in connection with conversion of October Notes 2,166,000                 $ 1,000               2,165,000  
Number of Common Stock Issued through Conversion         139                            
Issuance of common stock in connection with conversion of October Notes (450,000)                                 (450,000)  
Series D preferred stock exchanged for Series F preferred stock in connection with Exchange Agreements         (1,197)   1,847                        
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements (in shares)             3,198 3,583                      
Conversion of Demand Notes and October Notes into Series F preferred stock in connection with Exchange Agreements 1,276,000                                 1,276,000  
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements (in shares)             206   1,153                    
Conversion of January Notes into Series F preferred stock in connection with Exchange Agreements 82,000                                 82,000  
Issuance of Series F-1 preferred stock 1,372,000                                 1,372,000  
Issuance of Series F-2 preferred stock 464,000                                 464,000  
Commitment to issue shares of common stock in connection with January Notes 2,410,000                                 2,410,000  
Commitment to issue shares of common stock in connection with LOC Notes 230,000                                 230,000  
Commitment to issue shares of Series E preferred stock in connection with LOC Notes (in shares)           (5,000)                          
Commitment to issue shares of Series E preferred stock in connection with LOC Notes 3,363,000                                 3,363,000  
Commitment to issue shares of common stock in connection with Demand Notes 286,000                                 286,000  
Issuance of common stock upon the conversion of Series E preferred stock (in shares)                   556                  
Stock-based compensation 132,000                                 132,000  
Net loss (14,519,000)                                   (14,519,000)
Ending balance (in shares) at Jun. 30, 2023   251 1,443 500,756 0 0 5,251 3,583 1,153 7,139                  
Balance as of ending of period at Jun. 30, 2023 4,557,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 6,000               109,381,000 (104,830,000)
Beginning balance (in shares) at Dec. 31, 2023   251 1,443 500,756 0 0 4,448 653 1,153 171,677,000                  
Balance as of beginning of period at Dec. 31, 2023 4,677,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0               $ 7,000 121,665,000 (116,995,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Issuance of common stock/at-the-market offering, net of offering costs 588,000                                 588,000  
Issuance of common stock in connection with equity line of credit (in shares)                   140,904                  
Issuance of common stock in connection with equity line of credit 1,391,000                                 1,388,000  
Issuance of common stock/at-the-market offering, net of offering costs (in shares)                   32,163                  
Stock-based compensation 274,000                                 274,000  
Net loss (4,612,000)                                   (4,612,000)
Ending balance (in shares) at Mar. 31, 2024   251 1,443 500,756 0 0 4,448 653 1,153 344,744                  
Balance as of ending of period at Mar. 31, 2024 2,318,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0               10,000 123,915,000 (121,607,000)
Beginning balance (in shares) at Dec. 31, 2023   251 1,443 500,756 0 0 4,448 653 1,153 171,677,000                  
Balance as of beginning of period at Dec. 31, 2023 4,677,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0               $ 7,000 121,665,000 (116,995,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net proceeds on sales (in Shares)                                 32,163    
Net loss (9,641,000)                                    
Ending balance (in shares) at Jun. 30, 2024   0 0 0 0 0 0 0 0 3,307,872                  
Balance as of ending of period at Jun. 30, 2024 8,782,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0               $ 0 135,418,000 (126,636,000)
Beginning balance (in shares) at Mar. 31, 2024   251 1,443 500,756 0 0 4,448 653 1,153 344,744                  
Balance as of beginning of period at Mar. 31, 2024 2,318,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0               10,000 123,915,000 (121,607,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Issuance of common stock in connection with conversion of notes (in shares)   (251) (1,443) (500,756)     (4,448) (653) (1,153)   36,220 220,782 78,056 648,441 113,576 140,264      
Issuance of common stock in connection with equity line of credit (in shares)                   1,599,123                  
Issuance of common stock in connection with equity line of credit 9,343,000                                 9,343,000  
Issuance of common stock upon the conversion of Series E preferred stock (in shares)                   126,666                  
Reclassification of common stock to additional paid-in capital to reflect no change in par value in connection with reverse stock split 0                                 10,000  
Stock-based compensation 2,150,000                                 2,150,000  
Net loss (5,029,000)                                   (5,029,000)
Ending balance (in shares) at Jun. 30, 2024   0 0 0 0 0 0 0 0 3,307,872                  
Balance as of ending of period at Jun. 30, 2024 $ 8,782,000 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0 $ 0               $ 0 $ 135,418,000 $ (126,636,000)